Myopia Control
Stopping Myopia Progression is Coming into Focus
Approximately 1 billion children in the world today ages 6 years and 23 years, suffer from Myopia / Nearsightedness.
Myopia Control Efficacy & Safety
LLRL (low-level red-light therapy) has been utilized for several years to the slow progression of myopia. LLRL has been proven to slow myopia progression and has a reported efficacy of ~88%. As of today, LLRL has the highest efficacy in slowing myopia progression of any of the myopia control options. By way of comparison LLRL has an efficacy of ~ 88%, an oral tablet being developed to control myopia progression is showing an efficacy of ~ 75%, low dose atropine combined with myopia control lens wear has an efficacy of ~72%, and the efficacy of myopia control lenses range from ~40% to 65% depending upon the brand. Eye health safety associated with myopia control lenses is excellent. In addition, myopia control lenses have the least reported myopia rebound.
100% Reported Efficacy
Most recently, two (2025) different independent research studies have reported that the combination of myopia control lenses with LLRL could actually stop myopia progression with a near 100% efficacy. in addition, a 2025 study showed that when stimulating the peripheral retina with LLRL the myopia control signal was actually stronger than when stimulating the central retina. Given these positive results one would think that LLRL would be the gold standard for myopia control. However, in 2024 and 2025 two different articles have questioned the safety of LLRL due to the intensity and repetition of red-light exposure to the macula and fovea of the eye of the subject. These two studies suggested possible damage of the macular and fovea.
NeuroRays™ Eclipse PBM System
NeuroRays had already anticipated potential health problems of the macula with ocular light therapy and invented and patented the world’s first ocular light therapy system capable of providing ocular light therapy, while at the same time protecting the macula and fovea of the eye of the subject receiving the therapy. The system is called the NeuroRays Eclipse PBM System. In a similar manner in which the moon causes a solar eclipse, a fixation target used with the NeuroRays Eclipse PBM system imparts a protective image over all or part of the macula when ocular light therapy is being provided. The Eclipse PBM system is agnostic as to the type of light that is utilized and will work for (by way of example only) Red, Cyan, or Blue light therapy. While the Eclipse PBM system was originally designed for ocular light therapy for myopia control, the system can be used for other disorders also, such as by example only, dry AMD, diabetic retinopathy, meibomian gland dysfunction resulting in the dry eyes, mood disorders, seasonal affective disorder (SAD) and more.